대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Conversion to mTOR inhibitors in kidney transplant recipients with de novo cancers
저자	Aigerim Kalzhan, Nazym Nigmatullina
출판정보	2020; 2020(1):
키워드	? cancer \| everolimus \| kidney transplant \| sirolimus \| de novo
초록	To investigate the impact of mammalian target of rapamycin (mTOR) inhibitor conversion together with minimization of calcineurin inhibitor on allograft outcome and patient survival in kidney transplant recipients with post-transplant cancers. A retrospective study of all kidney transplant recipients diagnosed to have post-transplant cancers between the period 2010 and 2019. Patients were divided into 2 groups: mTOR inhibitor group and non-conversion group. Outcome included allograft function, patient survival, graft survival, acute rejection and cancer recurrence. 180 patients (56 in mTOR inhibitor group and 124 in non-conversion group) were analyzed. Median follow up was 36 months (range: 1 month – 20 years). The allograft function at 1-year remained similar between both groups. There was no significant difference in the patient survival, graft survival and rejection free survival between both groups. More patients in the non-conversion group developed recurrence of cancers than mTOR inhibitor group but statistically not significant. Use of mTOR inhibitors together with calcineurin inhibitor minimization offer a reasonable option in kidney transplant recipients who developed post-transplant cancers in view of stable renal function, low rejection rate and low cancer recurrence rate.
원문(PDF)	PDF 원문보기

목록

위로가기